# Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma

> **NCT00392340** · PHASE2 · UNKNOWN · sponsor: **Children's Cancer and Leukaemia Group** · enrollment: 63 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** topotecan hydrochloride
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00392340
- **Lead sponsor:** Children's Cancer and Leukaemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2010-01
- **Final completion:** —
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392340, "Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00392340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*